Publications – Nichi Glucan range of products

Nichi Glucan range of products

Journals

2023-08:(N-163) Acta Myologica 2023. 2023 Dec 20

Raghavan K, Sivakumar T, Ichiyama K, Yamamoto N, Balamurugan M, Dedeepiya VD, Senthilkumar R, Preethy S, Abraham S
Efficacy of N-163 beta-glucan in beneficially improving biomarkers of relevance to muscle function in patients with muscular dystrophies in a pilot clinical study
doi: 10.36185/2532-1900-312

2023-07:(N-163) Nature Scientific Reports 13, 17008 (2023)

Preethy S, Aoki Y, Minegishi K, Iwasaki M, Senthilkumar R, Abraham S
Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced β-glucan
doi: 10.1038/s41598-023-44330-0

2023-06:(N-163)　　J Smooth Muscle Res. 2023; 59: 67-80

Preethy S, Yamamoto N, Osaza S, Raghavan R, Dedeepiya V, Iwasaki M, Abraham S
Re-examining the therapeutic management of muscular dystrophies from a vascular smooth muscle-centred approach.
doi: 10.1540/jsmr.59.67.

2023-05:(N-163) IBRO Neuroscience reports 2023; 15: 90-99

Raghavan K, Dedeepiya VD, Srinivasan S, Pushkala S, Bharatidasan SS, Ikewaki N, Iwasaki M, Senthilkumar R, Preethy S, Abraham SJK
Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study.
doi: 10.1016/j.ibneur.2023.06.007.

2023-04: (AFO-202, N-163) 　 Aging Res & Lifestyle

Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Dedeepiya VD, Senthilkumar R, Preethy S, Abraham S.
Beta 1,3-1,6 glucans produced by two novel strains of Aureobasidium pullulans exert immune and metabolic beneficial effects in healthy middle-aged Japanese men: Results of an exploratory randomized control study,br> doi: 10.14283/jarlife.2023.11

2023-03: (AFO-202,N-163)　GEORGIAN MEDICAL NEWS No 3 (336) 2023

S Preethy , N Yamamoto , N Liem , S Bharatidasan , M Iwasaki , S Abraham.
Role of gut microbiome homeostasis, integrity of the intestinal epithelial cells, and the (endogenous) butyrate in enduring a healthy long life
doi: 10.1159/000527728

2023-02: (AFO-202) 　JAMA Pediatr Published online April 03, 2023

Zeyan Liew, Qi Meng, Qi Yan, et al.
Gut microbiome evaluation in children with autism spectrum disorder after increased maternal lithium consumption, may throw further insight. Comment to: Liew Z, Meng Q, Yan Q, et al. Association Between Estimated Geocoded Residential Maternal Exposure to Lithium in Drinking Water and Risk for Autism Spectrum Disorder in Offspring in Denmark. doi: 10.1001/jamapediatrics.2023.0346

2023-01: (AFO-202)　Vaccine 2023

Ikewaki N, Kurosawa G, Levy GA, Preethy S, Abraham S.
Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and Beta Glucans as a safer strategy in management doi: 10.1016/j.vaccine.2023.03.005.

2022-10:（AFO-202）　Med Princ Pract

Preethy S, Raghavan K, Ikewaki N, Abraham SJ.
Qualitative Evaluation of α-Synuclein – A Critical Step in Unraveling the Complexities of Autism Spectrum Disorder
https://www.karger.com/Article/FullText/527728

2022-09:（AFO-202, N-163）　BMJ Open Gastroenterology

Preethy S, Ikewaki N, Levy GA, Raghavan K, Dedeepiya VD, Yamamoto N, Srinivasan S, Ranganathan N, Iwasaki M, Senthilkumar R, Abraham SJK.
Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential for applications in human health and disease
https://pubmed.ncbi.nlm.nih.gov/36167455/

2022-08:（AFO-202, N-163）　Frontiers in Immunology

Preethy S, Raghavan K, Dedeepiya VD, Suryaprakash V, Ikewaki N, Ikeue Y, Nagataki M, Iwasaki M, Senthilkumar R, Abraham S.
Beneficial immune regulation by biological response modifier glucans in COVID-19 and their envisaged potentials in the management of sepsis
https://www.frontiersin.org/articles/10.3389/fimmu.2022.870632/full

2022-07:（AFO-202）　Journal of Alzheimer’s Disease

Preethy S, Ranganathan N, Raghavan K, Dedeepiya VD, Ikewaki N, Abraham S.
Integrating the Synergy of the Gut Microbiome into Regenerative Medicine: Relevance to Neurological Disorders
https://doi.org/10.3233/JAD-220313

2022-06:（AFO-202）　Journal of Food Biochemistry

Ikewaki, N., Kurosawa, G., Kisaka, T. and Abraham, S.J.K. (2022),
Controlled modulation of all the arms of the immunity including innate immunity by biological response modifier glucans, a simple yet potential nutritional supplement strategy to fight COVID-19
https://doi.org/10.1111/jfbc.14156

2022-05:（AFO-202）　Journal of Alzheimer’s disease

Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M,Kandaswamy R, Senthilkumar R, Preethy S, Abraham SJK.
Benefits of Gut Microbiota Reconstitution by Beta 1,3-1,6 Glucans in Subjects with Autism Spectrum Disorder and Other Neurodegenerative Diseases
https://pubmed.ncbi.nlm.nih.gov/36093695/

2022-04: (AFO-202, N-163)　 Journal of Diabetes and Metabolic Disorders

Ikewaki N, Onaka T, Ikeue Y, Nagataki M, Kurosawa G, Dedeepiya VD, Rajmohan M, Vaddi S, Senthilkumar R, Preethy S, Abraham SJK.
Beneficial effects of 1,3–1,6 β-glucans produced by Aureobasidium pullulans on non-esterified fatty acid levels in diabetic KKAy mice and their potential implications in metabolic dysregulation
https://doi.org/10.1007/s40200-022-01170-5

2022-03: (AFO-202, N-163)　 Brain and Behavior

Raghavan K, Dedeepiya VD, Kandaswamy R, Balamurugan M, Ikewaki N, Sonoda T, Kurosawa K, Iwasaki M, Preethy S, Abraham SJK.
Improvement of sleep and melatonin in children with autism spectrum disorder after β-1,3/1,6-glucan consumption: An open-label prospective pilot clinical study
https://doi.org/10.1002/brb3.2750

2022-02: (AFO-202, N-163）　Journal of Clinical and Experimental Hepatology

Nobunao Ikewaki, Gary A. Levy, Gene Kurosawa, Masaru Iwasaki, Vidyasagar D. Dedeepiya, Suryaprakash Vaddi
Rajappa Senthilkumar, Senthilkumar Preethy, Samuel J.K. Abraham
Hepatoprotective Effects of Aureobasidium pullulans Derived β 1,3–1,6 Glucans in a Murine Model of Non-alcoholic Steatohepatitis
https://www.sciencedirect.com/science/article/pii/S0973688322001608

2022-01: (AFO-202) 　BMJ Neurology Open

Raghavan K, Dedeepiya VD, Ikewaki N, Sonoda T, Iwasaki M, Preethy S, Abraham SJK.
Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomized, parallel-group pilot clinical study.
http://dx.doi.org/10.1136/bmjno-2021-000203

2021-05: (AFO-202, N-163) 　Clinical Immunology Communications

Ikewaki N, Raghavan K, Dedeepiya VD, Suryaprakash V, Iwasaki M, Preethy S, senthilkumar R, Abraham SJK.
Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulans AFO-202 and N-163 produced beta glucans in Sprague Dawley rats
https://www.sciencedirect.com/science/article/pii/S2772613421000081?via%3Dihub

2021-04: (AFO-202)　 Oncology Reports

Ikewaki N, Dedeepiya VD, Raghavan K, Rao K, Vaddi S, Osawa H, Kisaka T, Kurosawa G, Srinivasan S, Ganesakumar SRB, Senthilkumar R, Iwasaki M, Preethy S, Abraham SJK.
β‑glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B‑VACCIEN) in specific immunocompromised populations (Review)
https://www.spandidos-publications.com/10.3892/or.2021.8225

2021-03: (AFO-202, N-163) 　Biomedicine & Pharmacotherapy

Raghavan K, Dedeepiya VD, Suryaprakash V, Rao KS, Ikewaki N, Sonoda T, Levy GA, Iwasaki M, Senthilkumar R, Preethy S, Abraham SJK.
Beneficial Effects of novel Aureobasidium Pullulans strains produced Beta-1,3-1,6 Glucans on Interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study
https://www.medrxiv.org/content/10.1101/2021.08.09.21261738v1

2021-02: (AFO-202) 　Human Vaccines & Immunotherapeutics

Ikewaki N, Iwasaki M, Kurosawa G, Rao KS, Beitia JL, Preethy S, Abraham SJK.
β-Glucans: Wide-spectrum Immune-balancing Food-supplement-based Enteric (β-WIFE) Vaccine Adjuvant Approach to COVID-19
https://pubmed.ncbi.nlm.nih.gov/33651967/

2021-01: (AFO-202) 　Frontiers in Immunology

Ikewaki N, Dedeepiya VD, Iwasaki M, Abraham SJK.
Commentary: Beyond “TRIM” benefits of β-glucan by blood glucose and lipid balancing potentials in its defense Against COVID-19
https://www.frontiersin.org/articles/10.3389/fimmu.2021.620658/full

2020-03: (AFO-202) 　Frontiers in Immunology

Rao K-S, Suryaprakash V, Senthilkumar R, Preethy S, Katoh S, Ikewaki N, Abraham SJK.
Role of Immune Dysregulation in Increased Mortality Among a Specific Subset of COVID-19 Patients and Immune-Enhancement Strategies for Combatting Through Nutritional Supplements
https://www.frontiersin.org/articles/10.3389/fimmu.2020.01548/full

2020-02: (AFO-202) 　Thrombosis Journal

Ikewaki N, Rao KS, Archibold AD, Iwasaki M, Senthilkumar R, Preethy S, Katoh S, Abraham SJK.
Coagulopathy associated with COVID-19 – Perspectives & Preventive strategies using a Biological Response Modifier Glucan. Thromb J. 2020. doi: 10.1186/s12959-020-00239-6
https://thrombosisjournal.biomedcentral.com/articles/10.1186/s12959-020-00239-6

2020-01: (AFO-202)　　Journal of Diabetes & Metabolic Disorders volume

Ikewaki N, Iwasaki M, Abraham SJK.
Biological response modifier glucan through balancing of blood glucose may have a prophylactic potential in COVID-19 patients.
https://link.springer.com/article/10.1007/s40200-020-00664-4

2014-01: (AFO-202)　　Journal of Dietary Supplement

Jegatheesan Saravana Ganesh,Yegneswara Yellury Rao,Ratnagiri Ravikumar,Gosalakkal A. Jayakrishnan,Masaru Iwasaki,Senthilkumar Preethy &Samuel JK AbrahamIkewaki N, Iwasaki M, Abraham SJK.
Beneficial effects of Black yeast derived 1-3, 1-6 beta glucan- Nichi Glucan in a dyslipidemic individual of Indian origin A case report.
https://www.tandfonline.com/doi/full/10.3109/19390211.2013.859211

2012-01: (AFO-202)　　Case Reports in Medicine

Dedeepiya V, Sivaraman G,Venkatesh A, Preethy S, Abraham SJK.
Potential Effects of Nichi Glucan as a Food Supplement for Diabetes Mellitus and Hyperlipidemia; Preliminary Findings from the Study on Three Patients from India
https://www.hindawi.com/journals/crim/2012/895370/

Preprints

５）　(N-163)

Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Iwasaki M, Dinassing A, Senthilkumar R, Preethy S, Abraham SJK.
Randomised trial of Aureobasidium pullulans-produced beta 1,3-1,6-glucans in patients with Duchenne muscular dystrophy: Favourable changes in gut microbiota and clinical outcomes indicating their potential in epigenetic manipulation.
medRxiv 2022.12.09.22283273; doi: 10.1101/2022.12.09.22283273

４）　 (N-163)

Preethy S, Aoki Y, Minegishi K, Senthilkumar R, Abraham S.
Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced biological response modifier β-glucan (BRMG).
bioRxiv 2022.11.17.516628; doi: 10.1101/2022.11.17.516628

３）　(AFO-202, N-163)

Pushkala S, Seshayyan S, Theranirajan E, Sudhakar D, Raghavan K, Dedeepiya VD, Ikewaki N,Iwasaki M, Preethy S, Abraham S.
Efficient control of IL-6, CRP and Ferritin in Covid-19 patients with two variants of Beta-1,3-1,6 glucans in combination, within 15 days in an open-label prospective clinical trial.
https://www.medrxiv.org/content/10.1101/2021.12.14.21267778v1

２)　（N-163）

Raghavan K, Dedeepiya VD, Srinivasan S, Pushkala S, Subramanian S, Ikewaki N, Iwasaki M, Senthilkumar R, Preethy S, Abraham S.
Disease-modifying immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-label, prospective, randomized, comparative clinical study
https://www.medrxiv.org/content/10.1101/2021.12.13.21267706v1

１）（AFO-202, N-163）

Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Dedeepiya VD, Senthilkumar R, Preethy S, Abraham SJK.
Immune and metabolic beneficial effects of Beta 1,3-1,6 glucans produced by two novel strains of Aureobasidium pullulans in healthy middle-aged Japanese men: An exploratory study
https://www.medrxiv.org/content/10.1101/2021.08.05.21261640v1